OXB Messy Chart Long OXB.L Oxford Biomedical long, double bullflag kinda pattern happening.
Bio companies still popular right now.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0 GBP
−43.19 M GBP
128.80 M GBP
82.72 M
About Oxford BioMedica plc
Sector
Industry
CEO
Frank Mathias
Website
Headquarters
Oxford
Founded
1996
ISIN
GB00BDFBVT43
FIGI
BBG000BMB7T9
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.
Related stocks
Breakout on OXBThe Head and Shoulders pattern since 2008 has completed.
If the breakout continues, the target is 1264p.
Backed by substantive news, makes OXB, in my opinion, a strong buy. DYOR
Target on Oxford Biomedica (monthly chart)If OXB continues to head higher, then the target
is the height of the Head in the H&S pattern
formed on the monthly chart.
Good news for Oxford BiomedicaAfter multiple tests of resistance,
it looks as if OXB is going to break 11p and move higher
$OXB A six month consolidation before a bullish move this week.$OXB A six month consolidation before a bullish move this week.
Formed a symmetrical triangle with 3 touches on each side before the breakout.
Multibag; or not?A clear breakout for OXB
However, can it sustain the upward
momentum and break past 13p and head towards 20p.
OXB heading higher?Has broken above resistance in late 2015 (1)
RSI and MACD are heading the right direction (2)
and Moving averages are in alignment (3)
OXB - Saucer formation, wait for drop back, then long.Month's in the waiting, like the look of this one now, but waiting for a drop back (handle?) in seeking the optimum entry point. Potential cross of 200MA not too far away now as time progresses. RSI & MACD turning, so good chance of seeing the drop back. 3.60 and the 50MA looks good to me. LSE:OXB
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OXB is 582 GBX — it has decreased by −6.51% in the past 24 hours. Watch Oxford BioMedica plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Oxford BioMedica plc stocks are traded under the ticker OXB.
OXB stock has fallen by −0.67% compared to the previous week, the month change is a 10.99% rise, over the last year Oxford BioMedica plc has showed a 61.67% increase.
We've gathered analysts' opinions on Oxford BioMedica plc future price: according to them, OXB price has a max estimate of 930.00 GBX and a min estimate of 380.00 GBX. Watch OXB chart and read a more detailed Oxford BioMedica plc stock forecast: see what analysts think of Oxford BioMedica plc and suggest that you do with its stocks.
OXB stock is 2.61% volatile and has beta coefficient of 1.23. Track Oxford BioMedica plc stock price on the chart and check out the list of the most volatile stocks — is Oxford BioMedica plc there?
Today Oxford BioMedica plc has the market capitalization of 707.87 M, it has decreased by −2.00% over the last week.
Yes, you can track Oxford BioMedica plc financials in yearly and quarterly reports right on TradingView.
Oxford BioMedica plc is going to release the next earnings report on Feb 25, 2026. Keep track of upcoming events with our Earnings Calendar.
OXB earnings for the last half-year are −0.25 GBX per share, whereas the estimation was −0.24 GBX, resulting in a −5.12% surprise. The estimated earnings for the next half-year are −0.06 GBX per share. See more details about Oxford BioMedica plc earnings.
Oxford BioMedica plc revenue for the last half-year amounts to 73.22 M GBX, despite the estimated figure of 72.65 M GBX. In the next half-year revenue is expected to reach 92.00 M GBX.
OXB net income for the last half-year is −26.36 M GBP, while the previous report showed −10.71 M GBP of net income which accounts for −146.24% change. Track more Oxford BioMedica plc financial stats to get the full picture.
No, OXB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 25, 2025, the company has 861 employees. See our rating of the largest employees — is Oxford BioMedica plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oxford BioMedica plc EBITDA is −9.16 M GBP, and current EBITDA margin is −18.08%. See more stats in Oxford BioMedica plc financial statements.
Like other stocks, OXB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oxford BioMedica plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oxford BioMedica plc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oxford BioMedica plc stock shows the buy signal. See more of Oxford BioMedica plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.